Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.50 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13781334 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14268514 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL13780934 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL5172619 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL23602189 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL24299983 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14819154 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL16392567 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL15334479 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL687196 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111615400-B | Accurate glycoconjugates as therapeutic tools | 科纳克斯资本 | 2025-05-02 | — | — | CN | disclosed |
| EP-4446336-A2 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | Koranex Capital (CA) | 2024-10-16 | — | — | EP | disclosed |
| US-20240216491-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2024-07-04 | — | — | US | disclosed |
| US-11925680-B2 | Neoglycoconjugates as vaccines and therapeutic tools | KORANEX CAPITAL (CA) | 2024-03-12 | — | — | US | disclosed |
| EP-4277914-A1 | PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL | Koranex Capital (CA) | 2023-11-22 | — | — | EP | disclosed |
| CN-116981678-A | Method for synthesizing reactive carbohydrates comprising antigen precursors for conjugation to a carrier material | 科兰克斯资本 | 2023-10-31 | — | — | CN | disclosed |
| CN-115003330-A | Novel glycoconjugates as vaccines and diagnostic tools | 科纳克斯资本 | 2022-09-02 | — | — | CN | disclosed |
| EP-4034159-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | Koranex Capital (CA) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022150924-A1 | PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL | KORANEX CAPITAL (CA) | 2022-07-21 | — | — | WO | disclosed |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-07-29 | — | — | US | disclosed |
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| EP-3768309-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | Koranex Capital (CA) | 2021-01-27 | — | — | EP | disclosed |
| US-20200261560-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| US-10610576-B2 | Precision glycoconjugates as therapeutic tools | KORANEX CAPITAL (CA) | 2020-04-07 | — | — | US | disclosed |
| US-20190290746-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2019-09-26 | — | — | US | disclosed |
| WO-2019178699-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019075357-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | MAPK1 4496/4885ALDH1A1 3065/4885THRB 4436/4885 |
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SMN1; SMN2, RBM17, RBM22 | MAPK1 4806/4885ALDH1A1 2965/4885THRB 4657/4885 |
| US-10610576-B2 | Precision glycoconjugates as therapeutic tools | STT3B, STT3A, SIGLEC7 | MAPK1 3839/4885ALDH1A1 1454/4885THRB 2935/4885 |
| US-20240216491-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | MAPK1 4321/4885ALDH1A1 1745/4885THRB 4154/4885 |
| US-20190290746-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | STT3B, STT3A, SIGLEC7 | MAPK1 3839/4885ALDH1A1 1454/4885THRB 2935/4885 |
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-20200261560-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | STT3B, STT3A, SIGLEC7 | MAPK1 3839/4885ALDH1A1 1454/4885THRB 2935/4885 |
| US-11925680-B2 | Neoglycoconjugates as vaccines and therapeutic tools | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.